Bay Area Biotech: Companies, Startups and the Silicon Valley Ecosystem

Bay Area Biotech at a Glance

The San Francisco Bay Area is where the biotech industry began and, with Boston/Cambridge, one of its two largest centers today. GEN’s 2026 ranking of US biopharma clusters places it second, behind Boston/Cambridge, and CBRE’s 2025 talent report also ranks it second for life-sciences R&D talent. What sets the region apart is capital: Bay Area biotechs raised $7.8 billion of venture funding in 2025, more than any other US cluster.

For context on how the Bay Area compares with Boston, San Diego and the major European and Asian hubs, see our guide to global biotech hubs.

From Genentech to Today

The Bay Area’s lead in biotech goes back to a single scientific advance. In the early 1970s, Herbert Boyer at UCSF and Stanley Cohen at Stanford developed recombinant DNA technology, the ability to insert a gene into bacteria so they produce a human protein. In 1976 Boyer and the venture capitalist Robert Swanson, backed by Kleiner Perkins, founded Genentech to turn that technique into medicines, and the company is widely regarded as the world’s first biotechnology company.

Genentech went public in 1980, and its recombinant human insulin, licensed to Eli Lilly and sold as Humulin, reached the market in 1982. Roche took a majority stake in 1990 and full control in 2009, but Genentech still operates from its South San Francisco campus, where it celebrated its 50th anniversary in April 2026. Over five decades, the alumni of Genentech, Gilead and the region’s universities have founded or led a large share of the Bay Area’s biotech companies, which is the real engine of the cluster.

Where Biotech Sits in the Bay Area

“Bay Area biotech” covers several distinct districts, each with its own character.

• South San Francisco. The industry’s historic center. Genentech was founded here in 1976 by Herb Boyer and Robert Swanson in a small industrial warehouse, and the city still calls itself the “Birthplace of Biotechnology”. In April 2026 it counted nearly 250 active biotech companies.
• San Francisco and Mission Bay. Built around the University of California, San Francisco campus, with the Chan Zuckerberg Biohub, start-ups and incubator space nearby.
• The Peninsula and Silicon Valley. Foster City (Gilead), Redwood City (Revolution Medicines), San Carlos and, further south, Palo Alto around Stanford University and the Arc Institute.
• The East Bay. Emeryville and Berkeley around the University of California, Berkeley; Alameda (Exelixis); Hayward (Arcus Biosciences); and Pleasanton (10x Genomics).
• The North Bay. San Rafael, home of BioMarin, a leading rare-disease company.

The Research Institutions Behind the Cluster

Most Bay Area biotechs trace their science to a small number of institutions within an hour of each other.

• University of California, San Francisco (UCSF): a health-sciences university whose Mission Bay campus sits at the center of San Francisco’s biotech district, and the academic home of Herbert Boyer’s early recombinant DNA work.
• Stanford University: its medical school and engineering programs feed both biotech and medical devices, and the university sits next to Silicon Valley’s venture firms.
• University of California, Berkeley: a center for chemistry, bioengineering and genome editing, with Lawrence Berkeley National Laboratory on the hill above the campus.
• Independent institutes: the Gladstone Institutes in Mission Bay, the Arc Institute in Palo Alto and the Chan Zuckerberg Biohub in San Francisco fund long-horizon research that often leads to new companies.

For partners and investors, these institutions are also where to look for the next generation of assets: their technology-transfer offices license early discoveries, often to start-ups founded by the researchers themselves.

Leading Bay Area Biotech Companies

The table lists some of the best-known biotechs and tools companies headquartered in the region.

Medical technology adds another layer: Intuitive Surgical in Sunnyvale and Penumbra in Alameda are among the region’s largest device companies.

Startups, Investors and Incubators

The Bay Area’s start-up scene rests on its universities (UCSF, Stanford and UC Berkeley), on a deep bench of executives trained at Genentech, Gilead and other local companies, and on venture capital. Many of the most active life-sciences investors are based in the region, including Versant Ventures, 5AM Ventures and Foresite Capital in San Francisco, Samsara BioCapital in Palo Alto and the Bio + Health fund of Andreessen Horowitz in Menlo Park.

Early-stage companies have several places to start. QB3, the University of California’s life-sciences innovation institute, runs incubator space; Johnson & Johnson’s JLABS has a site in South San Francisco; and MBC BioLabs operates shared labs in San Francisco and San Carlos. For a founder, that infrastructure means a company can go from a university lab to a funded start-up with its own bench space quickly, which is one reason so many platform companies are founded here.

The flip side is concentration. Venture capital flows to the companies with the strongest data and the most experienced teams, and earlier-stage companies outside that group compete for the same investors with the rest of the country. For them, partnering revenue matters as much as the next equity round, which is where regional licensing comes in.

Silicon Valley Meets Biology

The overlap with the technology industry is the Bay Area’s distinctive advantage. The Arc Institute in Palo Alto and the Chan Zuckerberg Biohub in San Francisco are nonprofit research institutes built around large-scale biology and computation. Calico, backed by Alphabet, and insitro, a machine-learning drug discovery company, are both based in South San Francisco. In January 2026, NVIDIA and Eli Lilly announced an AI co-innovation lab based in the Bay Area, with up to $1 billion of investment over five years and work expected to begin in South San Francisco.

For buyers and partners, that concentration means the Bay Area is where many AI-discovered molecules and AI drug-design platforms are first offered for partnership. Our guide to AI drug discovery companies and AI drug discovery deal tracker cover the leading players and the deals they have signed.

Bay Area vs Boston: How the Two Leading Hubs Differ

The Bay Area and Boston/Cambridge have traded the top spot in GEN’s ranking over the years, and they are often compared. The numbers in GEN’s 2026 edition show two different models.

Boston leads on academic research funding and lab space, built around a dense core in Kendall Square where large pharma R&D centers sit next to MIT and Harvard. The Bay Area leads on venture capital, jobs and patents, and is more spread out, with a stronger link to technology companies and platform businesses. For a company deciding where to base a US operation, the choice often comes down to which ecosystem its science, its investors and its likely partners belong to. Many companies end up with a presence in both.

The Challenges

The Bay Area’s strengths come with real costs. Scientists and engineers are expensive to hire and to house, and biotech competes with the technology industry for the same computational talent. Lab space, though more available after the building boom of recent years, is costly, as is housing for the people who work in it. And because venture capital concentrates on the companies with the strongest data and teams, many earlier-stage companies find that the region’s headline funding total does not translate into easy money for them.

Those pressures push Bay Area companies toward capital-efficient strategies: partnering earlier, running parts of development in lower-cost regions, and using regional licensing deals to fund programs. They are also a reason the region is so active in cross-border dealmaking, in both directions.

Recent Deals Involving Bay Area Companies

Two patterns stand out. Large buyers keep coming to the Bay Area for late-stage assets, as Roche did for 89bio’s MASH drug pegozafermin. And Asian pharma companies are active buyers and licensees: Astellas bought Audentes to build its gene therapy business, and Japanese and Chinese partners have taken regional rights to some of the region’s best-known drugs.

Why Bay Area Biotechs Partner With Asia

For a Bay Area biotech with a clinical-stage asset, Asian rights are often the most valuable thing it is not using. Licensing Greater China, Japan or Korea rights to a regional partner can bring three things at once:

• Non-dilutive capital. Upfront payments and milestones that fund the US program without selling more equity.
• Faster global development. A regional partner funds and runs local trials, often as part of a multi-regional study that also supports the US filing.
• Market access. Japan is the world’s fourth-largest pharmaceutical market and China the second, and both have their own approval systems and pricing rules that a local partner already knows.

The Exelixis and Takeda agreement is a textbook example: Takeda took exclusive rights to commercialize cabozantinib in Japan for $50 million upfront, $95 million in milestones for the first three indications and royalties, while Exelixis kept the rest of its territory. Cytokinetics followed a similar path in Greater China for aficamten, first with Ji Xing and later with Sanofi, keeping milestones of up to $150 million and royalties in the low to high teens.

Structuring a Regional Deal

Regional licensing works when it is designed not to get in the way of a later global deal. The points that matter most:

• Define the territory precisely. Greater China usually means mainland China, Hong Kong, Macau and Taiwan; Japan and Korea are often licensed separately.
• Keep global development aligned. Agree how the partner’s trials fit the global plan, who pays for what, and how data are shared in both directions.
• Protect future options. A large buyer of the global rights will want to know the regional deal can be bought out or coordinated. Change-of-control and buy-back terms should be considered from the start.
• Plan manufacturing and supply. Decide who supplies the regional partner and on what terms, and check supply-chain exposure under the BIOSECURE Act.
• Know the local regulator. Approval routes and bridging requirements differ; our Japan market entry guide and NMPA approval process guide cover the two largest markets.

Our cross-border licensing term sheet guide sets out typical economics, and our out-licensing team runs regional processes for US biotechs from first outreach to signed agreement.

What Bay Area Biotechs Need From Partners

In our work with US biotechs, the same four needs come up again and again.

• Capital without dilution. Regional licensing, co-development and option deals that bring in cash while the company keeps its most valuable territories.
• Patients and speed. Access to clinical sites and enrollment in Asia, often through a partner who runs the regional arm of a multi-regional trial. Our guide to CROs and CDMOs explains how that work is usually outsourced.
• Manufacturing that a future buyer will accept. Supply chains that work today and will not become a problem in a later global deal or under US policy.
• The right introductions. Business-development teams in Tokyo, Seoul and Shanghai receive far more proposals than they can review. A trusted introduction and a package prepared to their standards make the difference between a first meeting and a polite decline.

The Other Direction: Chinese Assets, US NewCos

The flow also runs the other way. Bay Area investors and executives are among the most active builders of NewCos: US-based companies created to develop a molecule licensed from a Chinese originator, with Western management and venture funding. Chinese out-licensing reached a record of roughly $136 billion in total deal value in 2025, according to our China Out-Licensing Report 2026, and a number of those assets have been placed in US NewCos.

For a Bay Area founder or investor, that creates a second route to a pipeline: in-license a clinical-stage asset from China rather than start from discovery. Our NewCo blueprint and guide to in-licensing from China explain how those companies are structured and what diligence they need.

The Bottom Line

The Bay Area remains one of the two most important biotech hubs in the world: the birthplace of the industry, the biggest magnet for biotech venture capital in 2025, and the meeting point of biology and artificial intelligence. Its companies are frequent targets for global buyers, and many of them have learned to use Asian partners to fund development without giving up their most valuable markets.

If you run a Bay Area biotech and want to explore licensing Greater China, Japanese or Korean rights, or you are building a company around an asset from China, talk to our team.